BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19893995)

  • 21. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy.
    Kurikka S
    Vaccine; 1996 Sep; 14(13):1239-42. PubMed ID: 8961512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
    Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A
    J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.
    Halperin SA; Langley JM; Hesley TM; Zappacosta PS; Radley D; Smith B; Hoffenbach A; Boslego J; Silber JL
    Hum Vaccin; 2005; 1(6):245-50. PubMed ID: 17012871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies prevalence against Haemophilus influenzae type b in Jeddah population, Saudi Arabia. II. Antibodies subclasses.
    Zarei AE; Redwan EM
    Hum Antibodies; 2019; 27(1):1-11. PubMed ID: 30103308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IgG subclasses and avidity of antibodies to polysaccharide antigens in allogeneic BMT recipients after vaccination with pneumococcal polysaccharide and Haemophilus influenzae type b conjugate vaccines.
    Parkkali T; Käyhty H; Anttila M; Ruutu T; Wuorimaa T; Soininen A; Volin L; Ruutu P
    Bone Marrow Transplant; 1999 Sep; 24(6):671-8. PubMed ID: 10490735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Avidity of specific IgG antibodies elicited by immunisation against Haemophilus influenzae type b.
    Agbarakwe AE; Griffiths H; Begg N; Chapel HM
    J Clin Pathol; 1995 Mar; 48(3):206-9. PubMed ID: 7730477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haemophilus influenzae type b-specific antibody in infants after maternal immunization.
    Englund JA; Glezen WP; Thompson C; Anwaruddin R; Turner CS; Siber GR
    Pediatr Infect Dis J; 1997 Dec; 16(12):1122-30. PubMed ID: 9427456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody.
    Lee YC; Kelly DF; Yu LM; Slack MP; Booy R; Heath PT; Siegrist CA; Moxon RE; Pollard AJ
    Clin Infect Dis; 2008 Jan; 46(2):186-92. PubMed ID: 18171249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth.
    Gatchalian S; Reyes M; Bernal N; Lefevre I; David MP; Han HH; Bock HL; Wolter J; Schuerman L
    Hum Vaccin; 2005; 1(5):198-203. PubMed ID: 17012860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies prevalence against Haemophilus influenzae type b in Jeddah population, Saudi Arabia. III. Antibodies avidity.
    Zarei AE; Redwan EM
    Hum Antibodies; 2019; 27(1):13-22. PubMed ID: 30103310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.
    Iro MA; Khatami A; Marshall AS; Pace D; Voysey M; McKenna J; Campbell D; Attard-Montalto S; Finn A; White C; Faust SN; Kent A; Heath PT; MacLeod E; Stanford E; Findlow H; Almond R; Bai X; Borrow R; Snape MD; Pollard AJ
    Lancet Infect Dis; 2015 Feb; 15(2):172-80. PubMed ID: 25577661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine.
    Nolan T; Altmann A; Skeljo M; Streeton C; Schuerman L
    Vaccine; 2004 Nov; 23(1):14-20. PubMed ID: 15519702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life.
    Gatchalian S; Reyes M; Bermal N; Chandrasekaran V; Han HH; Bock HL; Lefevre I
    Hum Vaccin; 2008; 4(1):60-6. PubMed ID: 18376148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia.
    Mulholland K; Suara RO; Siber G; Roberton D; Jaffar S; N'Jie J; Baden L; Thompson C; Anwaruddin R; Dinan L; Glezen WP; Francis N; Fritzell B; Greenwood BM
    JAMA; 1996 Apr; 275(15):1182-8. PubMed ID: 8609686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV Combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age.
    Gabutti G; Zepp F; Schuerman L; Dentico P; Bamfi F; Soncini R; Habermehl P; Knuf M; Crovari P;
    Scand J Infect Dis; 2004; 36(8):585-92. PubMed ID: 15370670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Four is better than nine. a combined diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine for routine immunization in Malaysia.
    Wong SL; Soosai P; Teoh YL; Han HH; Lefevre I; Bock HL
    Southeast Asian J Trop Med Public Health; 2008 May; 39(3):474-83. PubMed ID: 18564687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation and validation of a serum bactericidal antibody assay for Haemophilus influenzae type b and the threshold of protection.
    Townsend K; Ladhani SN; Findlow H; Borrow R
    Vaccine; 2014 Sep; 32(43):5650-6. PubMed ID: 25138290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.